A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis

NCT02603172 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

23

Enrollment

INDUSTRY

Sponsor class

Stopped A new study will be initiated in order to specifically investigate cardiac safety

Conditions

Amyloidosis

Interventions

DRUG: GSK3039294

Sponsor

GlaxoSmithKline